Evidence map›Paper›PMID 38455419›Full record

ArticleAmerican journal of cancer research2024

Arsenic trioxide suppresses lung adenocarcinoma stem cell stemness by inhibiting m6A modification to promote ferroptosis.

Wen Jin, Yu Sun, Jiaqi Wang, Yan Wang, Dan Chen, Ming Fang, Jie He, Linsheng Zhong, Hao Ren, Yuanmei Zhang and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Oxeiptosis - potential in cancer treatment?Expert reviews in molecular medicine · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Wen JinDepartment of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Yu SunDepartment of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Jiaqi WangDepartment of Oncology, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Yan WangDepartment of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Dan ChenDepartment of Oncology, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Ming FangDepartment of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Jie HeDepartment of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Linsheng ZhongDepartment of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Hao RenDepartment of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Yuanmei ZhangDepartment of Ultrasound, The First Affiliate Hospital of Guangzhou Medical University Guangzhou 510120, Guangdong, China.
Hao YinDepartment of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Shijia WuDepartment of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Ruqin ChenDepartment of Traditional Chinese Medicine, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Wen YanDepartment of Oncology, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Guangdong Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arsenic trioxide (ATO) is well known for its inhibitory effects on cancer progression, including lung adenocarcinoma (LUAD), but the molecular mechanism remains elusive. This study aimed to investigate the roles of ATO in regulating LUAD stem cells (LASCs) and the underlying mechanisms. To induce LASCs, cells cultured in an F12 medium, containing B27, epidermal growth factor, and basic fibroblast growth factor, induced LASCs. LASCs stemness was assessed through tumor sphere formation assay, and percentages of CD133+ cells were detected by flow cytometry. The Cell Counting Kit-8 method was used to assess LASCs viability, while reactive oxygen species (ROS) and iron ion levels were quantitated by fluorescence microscopy and spectrophotometry, respectively, and total m6A levels were measured by dot blot. Additionally, LASCs mitochondrial alterations were analyzed via transmission electron microscopy. Finally, the tumorigenicity of LASCs was assessed using a cancer cell line-based xenograft model. Tumor sphere formation and CD133 expression were used to validate the successful induction of LASCs from A549 and NCI-H1975 cells. ATO significantly inhibited proliferation, reduced ZC3H13 expression and total m6A modification levels, and increased ROS and iron ion content, but repressed sphere formation and CD133 expression in LASCs. ZC3H13 overexpression or ferrostatin-1 treatment abrogated LASCs stemness inhibition caused by ATO treatment, and interference with ZC3H13 inhibited LASCs stemness. Furthermore, the promotion of LASCs ferroptosis by ATO was effectively mitigated by ZC3H13 overexpression, while interference with ZC3H13 further promoted ferroptosis. Moreover, si-ZC3H13 promoted ferroptosis and impaired stemness in LASCs, which ferrostatin-1 abrogated. Finally, ZC3H13 overexpression alleviated the inhibitory effects of ATO on LASCs tumorigenicity. Taken together, ATO treatment substantially impaired the stemness of LUAD stem cells by promoting the ferroptosis program, which was mediated by its ZC3H13 gene expression inhibition to suppress m6A medication.

Indexed as

Arsenic trioxidecancer stem cellsferroptosislung adenocarcinomam6AZC3H13

Identifiers

PMID38455419
PMCPMC10915325
OpenAlexW4394741969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.